BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16043352)

  • 1. Molecular profile of androgen-independent prostate cancer xenograft LuCaP 23.1.
    Fina F; Muracciole X; Rocchi P; Nanni-Métellus I; Delfino C; Daniel L; Dussert C; Ouafik L'; Martin PM
    J Steroid Biochem Mol Biol; 2005 Sep; 96(5):355-65. PubMed ID: 16043352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft.
    Rocchi P; Muracciole X; Fina F; Mulholland DJ; Karsenty G; Palmari J; Ouafik L; Bladou F; Martin PM
    Oncogene; 2004 Dec; 23(56):9111-9. PubMed ID: 15489889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model.
    Cheng L; Zhang S; Sweeney CJ; Kao C; Gardner TA; Eble JN
    Anticancer Res; 2004; 24(4):2135-40. PubMed ID: 15330153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines.
    Rocchi P; Boudouresque F; Zamora AJ; Muracciole X; Lechevallier E; Martin PM; Ouafik L
    Cancer Res; 2001 Feb; 61(3):1196-206. PubMed ID: 11221851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
    Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increase in amphiregulin and epiregulin in prostate cancer xenograft after androgen deprivation-impact of specific HER1 inhibition.
    Tørring N; Hansen FD; Sørensen BS; Ørntoft TF; Nexø E
    Prostate; 2005 Jun; 64(1):1-8. PubMed ID: 15651060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration.
    Bladou F; Vessella RL; Buhler KR; Ellis WJ; True LD; Lange PH
    Int J Cancer; 1996 Sep; 67(6):785-90. PubMed ID: 8824549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.
    Stangelberger A; Schally AV; Zarandi M; Heinrich E; Groot K; Havt A; Kanashiro CA; Varga JL; Halmos G
    Prostate; 2007 Sep; 67(12):1339-53. PubMed ID: 17624923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prostatic environment suppresses growth of androgen-independent prostate cancer xenografts: an effect influenced by testosterone.
    Jennbacken K; Gustavsson H; Tesan T; Horn M; Vallbo C; Welén K; Damber JE
    Prostate; 2009 Aug; 69(11):1164-75. PubMed ID: 19399749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model.
    Knuuttila M; Yatkin E; Kallio J; Savolainen S; Laajala TD; Aittokallio T; Oksala R; Häkkinen M; Keski-Rahkonen P; Auriola S; Poutanen M; Mäkelä S
    Am J Pathol; 2014 Aug; 184(8):2163-73. PubMed ID: 24949550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer.
    Plymate SR; Haugk K; Coleman I; Woodke L; Vessella R; Nelson P; Montgomery RB; Ludwig DL; Wu JD
    Clin Cancer Res; 2007 Nov; 13(21):6429-39. PubMed ID: 17975155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
    Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
    Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol.
    Corey E; Quinn JE; Emond MJ; Buhler KR; Brown LG; Vessella RL
    Clin Cancer Res; 2002 Apr; 8(4):1003-7. PubMed ID: 11948106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
    Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes.
    Gregory CW; Hamil KG; Kim D; Hall SH; Pretlow TG; Mohler JL; French FS
    Cancer Res; 1998 Dec; 58(24):5718-24. PubMed ID: 9865729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T; Lin FF; Rao P; Lin MF
    Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LuCaP 35: a new model of prostate cancer progression to androgen independence.
    Corey E; Quinn JE; Buhler KR; Nelson PS; Macoska JA; True LD; Vessella RL
    Prostate; 2003 Jun; 55(4):239-46. PubMed ID: 12712403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
    Joseph IB; Nelson JB; Denmeade SR; Isaacs JT
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2507-11. PubMed ID: 9815654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors.
    Kiyama S; Morrison K; Zellweger T; Akbari M; Cox M; Yu D; Miyake H; Gleave ME
    Cancer Res; 2003 Jul; 63(13):3575-84. PubMed ID: 12839944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors.
    Snoek R; Cheng H; Margiotti K; Wafa LA; Wong CA; Wong EC; Fazli L; Nelson CC; Gleave ME; Rennie PS
    Clin Cancer Res; 2009 Jan; 15(1):39-47. PubMed ID: 19118031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.